PHARMEXA TO START GV1001 TRIAL

Pharmexa has submitted an application to initiate a Phase II trial of Heptovax. The trial will begin in the third quarter of 2006 and will include up to 41 liver cancer patients.

The Heptovax trial is an open-label study evaluating the safety and efficacy of GV1001 in advanced hepatocellular carcinoma (liver cancer). The trial will enroll patients from three centers in Spain, France and Germany.